168 related articles for article (PubMed ID: 25270710)
1. Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report.
Falivene S; Giugliano FM; Grimaldi AM; Di Franco R; Toledo D; Muto M; Cammarota F; Borzillo V; Ascierto PA; Muto P
BMC Dermatol; 2014 Sep; 14():15. PubMed ID: 25270710
[TBL] [Abstract][Full Text] [Related]
2. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.
Joseph K; Alkaabi K; Warkentin H; Ghosh S; Jha N; Smylie M; Walker J
J Med Imaging Radiat Oncol; 2019 Apr; 63(2):257-263. PubMed ID: 30549229
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab in non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of cetuximab in the treatment of squamous cell carcinoma.
Preneau S; Rio E; Brocard A; Peuvrel L; Nguyen JM; Quéreux G; Dreno B
J Dermatolog Treat; 2014 Oct; 25(5):424-7. PubMed ID: 23167307
[TBL] [Abstract][Full Text] [Related]
6. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG
Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920
[TBL] [Abstract][Full Text] [Related]
8. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.
Valeriani M; Muni R; Osti MF; De Sanctis V; Minniti G; Ardito F; Maurizi Enrici R
Radiol Med; 2012 Feb; 117(1):125-32. PubMed ID: 21892718
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial.
Mesía R; Rueda A; Vera R; Lozano A; Medina JA; Aguiar D; Árias F; Triana G; Carles J; López-López R
Ann Oncol; 2013 Feb; 24(2):448-453. PubMed ID: 23041591
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
15. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
Zwicker F; Roeder F; Thieke C; Timke C; Münter MW; Huber PE; Debus J
Strahlenther Onkol; 2011 Jan; 187(1):32-8. PubMed ID: 21234529
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
17. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.
Balermpas P; Hambek M; Seitz O; Rödel C; Weiss C
Strahlenther Onkol; 2009 Dec; 185(12):775-81. PubMed ID: 20013086
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
Kim S; Eleff M; Nicolaou N
Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases.
Giacchero D; Barrière J; Benezery K; Guillot B; Dutriaux C; Mortier L; Lacour JP; Thyss A; Peyrade F
Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):716-8. PubMed ID: 21831617
[No Abstract] [Full Text] [Related]
20. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Gaffney DC; Soyer HP; Simpson F
Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
